iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.21
(-0.93%)
SEK 0.21
(-0.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 293 Thousand SEK | -30337.4% |
| 2022 | 123 Thousand SEK | 110.81% |
| 2021 | -1.13 Million SEK | -114.89% |
| 2020 | 7.64 Million SEK | 134.71% |
| 2019 | -22.02 Million SEK | -105.24% |
| 2018 | -10.73 Million SEK | -126.51% |
| 2017 | -4.73 Million SEK | -225.19% |
| 2016 | -1.45 Million SEK | 39.09% |
| 2015 | -2.39 Million SEK | 0.0% |
| 2014 | - SEK | 100.0% |
| 2013 | -1.21 Million SEK | 8.64% |
| 2012 | -1.33 Million SEK | -5153.36% |
| 2011 | 26.41 Thousand SEK | 604.51% |
| 2010 | 3750.00 SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -3.85 Million SEK | -108.86% |
| 2024 Q1 | -632 Thousand SEK | 96.97% |
| 2024 Q2 | 361 Thousand SEK | 157.12% |
| 2023 Q1 | 211 Thousand SEK | -45.05% |
| 2023 Q3 | -269 Thousand SEK | -288.11% |
| 2023 Q2 | 143 Thousand SEK | -32.23% |
| 2023 Q4 | -20.84 Million SEK | -7648.33% |
| 2023 FY | -37.19 Million SEK | -30337.4% |
| 2022 Q2 | 58 Thousand SEK | -54.69% |
| 2022 FY | 123 Thousand SEK | 110.81% |
| 2022 Q3 | -447 Thousand SEK | -870.69% |
| 2022 Q1 | 128 Thousand SEK | 113.54% |
| 2022 Q4 | 384 Thousand SEK | 185.91% |
| 2021 Q2 | -65 Thousand SEK | -38.3% |
| 2021 Q4 | -945 Thousand SEK | -1066.67% |
| 2021 Q1 | -47 Thousand SEK | 92.97% |
| 2021 FY | -1.13 Million SEK | -114.89% |
| 2021 Q3 | -81 Thousand SEK | -24.62% |
| 2020 Q2 | 3.45 Million SEK | -22.15% |
| 2020 Q1 | 4.43 Million SEK | -0.74% |
| 2020 Q4 | -669 Thousand SEK | -258.91% |
| 2020 FY | 7.64 Million SEK | 134.71% |
| 2020 Q3 | 421 Thousand SEK | -87.81% |
| 2019 Q2 | 3.17 Million SEK | 559.57% |
| 2019 FY | -22.02 Million SEK | -105.24% |
| 2019 Q3 | 3.34 Million SEK | 5.46% |
| 2019 Q4 | 4.47 Million SEK | 33.7% |
| 2019 Q1 | -690 Thousand SEK | -133.33% |
| 2018 Q2 | -3.32 Million SEK | -59.23% |
| 2018 FY | -10.73 Million SEK | -126.51% |
| 2018 Q1 | -2.08 Million SEK | -19.58% |
| 2018 Q3 | 575 Thousand SEK | 117.28% |
| 2018 Q4 | 2.07 Million SEK | 260.0% |
| 2017 Q2 | -540 Thousand SEK | -127.93% |
| 2017 Q3 | -683.99 Thousand SEK | -26.67% |
| 2017 Q4 | -1.74 Million SEK | -155.53% |
| 2017 FY | -4.73 Million SEK | -225.19% |
| 2017 Q1 | -236.91 Thousand SEK | -182.3% |
| 2016 Q3 | -632.8 Thousand SEK | 85.75% |
| 2016 FY | -1.45 Million SEK | 39.09% |
| 2016 Q2 | -4.44 Million SEK | -2434.72% |
| 2016 Q1 | -175.2 Thousand SEK | 0.0% |
| 2016 Q4 | 287.86 Thousand SEK | 145.49% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 100.0% |
| 2015 FY | -2.39 Million SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 FY | - SEK | 100.0% |
| 2014 Q4 | -432.24 Thousand SEK | -109.57% |
| 2014 Q2 | 266.12 Thousand SEK | 200.0% |
| 2014 Q1 | -266.12 Thousand SEK | 58.81% |
| 2014 Q3 | -206.25 Thousand SEK | -177.5% |
| 2013 Q3 | -148.4 Thousand SEK | 51.69% |
| 2013 FY | -1.21 Million SEK | 8.64% |
| 2013 Q4 | -646.16 Thousand SEK | -335.42% |
| 2013 Q1 | -117.96 Thousand SEK | 60.66% |
| 2013 Q2 | -307.17 Thousand SEK | -160.39% |
| 2012 Q2 | 9899.00 SEK | -30.3% |
| 2012 FY | -1.33 Million SEK | -5153.36% |
| 2012 Q1 | 14.2 Thousand SEK | 0.0% |
| 2012 Q4 | -299.83 Thousand SEK | 7.16% |
| 2012 Q3 | -322.96 Thousand SEK | -3362.56% |
| 2011 FY | 26.41 Thousand SEK | 604.51% |
| 2010 FY | 3750.00 SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AddLife AB (publ) | 2.77 Billion SEK | 99.989% |
| Biotage AB (publ) | 1.14 Billion SEK | 99.974% |
| Bonesupport Holding AB (publ) | 533.12 Million SEK | 99.945% |
| Doxa AB (publ) | 9.9 Million SEK | 97.04% |
| Elekta AB (publ) | 6.77 Billion SEK | 99.996% |
| Ortivus AB (publ) | 30.84 Million SEK | 99.05% |
| Ortivus AB (publ) | 30.84 Million SEK | 99.05% |
| Q-linea AB (publ) | 995 Thousand SEK | 70.553% |
| S2Medical AB (publ) | 5.03 Million SEK | 94.183% |
| Synsam AB (publ) | 617 Million SEK | 99.953% |